Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Merck
Biotech
Alpine bails on phase 1 cancer asset after 2nd patient death
After a second patient death, Alpine Immune Sciences is terminating enrollment for two trials assessing its cancer asset davoceticept.
Gabrielle Masson
Oct 24, 2022 11:30am
ESMO: AstraZeneca's bispecific shows promise but limited by dose
Sep 11, 2022 4:20am
Novartis R&D chief Jay Bradner departs—Chutes & Ladders
Sep 2, 2022 9:30am
Racing Bayer, Merck gets FDA fast-track tag for anticoagulant
Aug 23, 2022 8:40am
Merck bets big on circular RNA, paying $150M to work with Orna
Aug 16, 2022 9:00am
Merck taps Saama to add AI to drug development process
Aug 10, 2022 10:42am
